Related Experiment Videos
New non-cytotoxic approaches to ovarian cancer
S B Kaye1, E A Eisenhauer, T C Hamilton
1CRC Department of Medical Oncology, University of Glasgow, UK. S.B.Kaye@beatson.gla.ac.uk
Abstract:
Two recent examples of conventional cytotoxic drugs, taxoids and topo I inhibitors, are set to make a real impact in the treatment of ovarian cancer. However, further progress may depend on novel approaches, focusing on other targets. This review will concentrate on those approaches which have already led to the initiation of clinical trials: agents designed to circumvent cellular drug resistance, signal transduction inhibitors, new hormonal agents, matrix metalloproteinase inhibitors, immunotherapy, immunotoxins and radioconjugates, and intraperitoneal genetic therapy, including the use of replicating viruses. In some cases, early clinical data are encouraging, but ultimately combined treatment with conventional agents may make most impact.
Insights
Novel ovarian cancer treatments show promise beyond conventional cytotoxic drugs. Future progress relies on targeting drug resistance, signaling pathways, and utilizing immunotherapy and gene therapy, potentially combined with existing agents.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian cancer treatment faces challenges with conventional cytotoxic drugs like taxoids and topoisomerase I inhibitors.
- Further advancements are needed to overcome limitations and improve patient outcomes.
Purpose of the Study:
- To review novel therapeutic strategies for ovarian cancer that have entered clinical trials.
- To assess the potential impact of these new approaches on ovarian cancer treatment.
Main Methods:
- Review of clinical trial data for novel ovarian cancer therapies.
- Focus on agents targeting drug resistance, signal transduction, hormonal pathways, matrix metalloproteinases, and novel modalities like immunotherapy, immunotoxins, radioconjugates, and intraperitoneal gene therapy.
- Inclusion of therapies using replicating viruses.
Main Results:
- Early clinical data for some novel agents are encouraging.
- Several new therapeutic avenues are being explored in clinical trials for ovarian cancer.
Conclusions:
- Novel approaches including drug resistance circumvention, signal transduction inhibitors, hormonal agents, matrix metalloproteinase inhibitors, immunotherapy, immunotoxins, radioconjugates, and intraperitoneal gene therapy show promise for ovarian cancer.
- Combined treatment strategies integrating novel agents with conventional therapies may offer the greatest clinical impact.